Category: Health Science
-
![Bionano Genomics (BNGO.Q) under the microscope, taking a look at a company you may have missed]()
Bionano Genomics (BNGO.Q) under the microscope, taking a look at a company you may have missed
Bionano Genomics (BNGO.Q) has been keeping busy lately, and the Company’s Q2 2021 Financial Results are a testament to their efforts. Bionano has been on my radar for quite some time, although I couldn’t really tell you why. After all, I don’t know the first thing about genomics, let alone science. In fact, I almost…
-
![Bionano Genomics (BNGO.Q) under the microscope, taking a look at a company you may have missed]()
Bionano Genomics (BNGO.Q) under the microscope, taking a look at a company you may have missed
Bionano Genomics (BNGO.Q) has been keeping busy lately, and the Company’s Q2 2021 Financial Results are a testament to their efforts. Bionano has been on my radar for quite some time, although I couldn’t really tell you why. After all, I don’t know the first thing about genomics, let alone science. In fact, I almost…
-
![To Invest or Not: Diagnos (ADK.V)]()
To Invest or Not: Diagnos (ADK.V)
In this episode, we talk about DIAGNOS (ADK.V), a publicly traded Canadian corporation with a mission to commercialize technologies combining contextual imaging, and traditional data mining thereby improving decision making processes. DIAGNOS offers products, services, and solutions to clients in a variety of fields including natural resources, healthcare, and entertainment. We discuss what they do,…
-
![Chris’ Corner: Diagnos Inc (ADK.V)]()
Chris’ Corner: Diagnos Inc (ADK.V)
Chris Parry speaks with Andre Larente, president and CEO of DIAGNOS (ADK.V) to get an in-depth look at how their diabetic retinopathy screening services work and what it means for optometrists and patients. Tune in!
-
![Diagnos (ADK.V) Renews Contract with Optina Diagnostics]()
Diagnos (ADK.V) Renews Contract with Optina Diagnostics
Diagnos (ADK.V) today announced a contract renewal to provide its telemedicine platform based on CARA (Computer Assisted Retina Analysis) to Optina Diagnostics for an additional three-year period. “This contract renewal is a testimony of the high quality of our telemedicine platform and the agility of DIAGNOS people to adapt its platform to enable the rich…
-
![First Glance with Jody Vance – Medexus Pharma (MDP.T)]()
First Glance with Jody Vance – Medexus Pharma (MDP.T)
Vancouver’s own Jody Vance speaks with Ken d’Entremont, Medexus Pharmaceuticals (MDP.V) CEO and director, to find out more about the company’s mandate of bringing established drugs approved in other countries to patients in Canada. Listen in! <div algn=”center:><iframe width=”803″ height=”452″ src=”https://www.youtube.com/embed/r4MwrGgePDo” title=”YouTube video player” frameborder=”0″ allow=”accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture” allowfullscreen></iframe></div>
-
![Today’s Idea: Medexus Pharmaceuticals (MDP.T) Continues to Climb the North American Pharmaceuticals Ladder]()
Today’s Idea: Medexus Pharmaceuticals (MDP.T) Continues to Climb the North American Pharmaceuticals Ladder
Cancer is a bitch. Even if you haven’t had to battle against cancer yourself, you likely know someone who has. Unfortunately for me, that person was my mom; however, before this turns into a sob story let me assure you that my mom is alive and well after kicking cancer’s ass. My mom was diagnosed…
-
![Medexus (MDP.V) by Mackie Research upgrades their target price by 42%]()
Medexus (MDP.V) by Mackie Research upgrades their target price by 42%
“Medicine is a science of uncertainty and an art of probability.” – William Osler I think it’s appropriate I start the article by saying that I get it, biotech is not an easy industry to understand. The jargon used by those writing about the industry often takes away from the ingenious business models of some…
-
![The top 10 most cashed up psychedelics companies right now]()
The top 10 most cashed up psychedelics companies right now
“In business, cash is oxygen” – Gary Vaynerchuk Psychedelics is a cash-intensive business. Earlier in the week, I wrote about how clinical trials alone cost companies tens, sometimes hundreds of millions of dollars. And that’s only part of the picture. According to Tufts Center for the Study of Drug Development, bringing a new FDA-approved drug…
-
Psychedelic Weekly Roundup with MNMD.Q, MSET.C, MYND.C, MEDI.NE, AWKN.NE, SILO, MCUR.C, NOVA.C, TRYP.C, TPIA, NEON.C
Another busy week in the psychedelic sector, with many smaller companies not always covered here at Equity Guru making news. Let’s start with the biggest players though. Mind Medicine (MNMD.Q, MMED.NE) MindMed announced that they have agreed to partner with Forian (FORA.Q), who provide evidence-based support for clinical and commercial decision making. Forian and MindMed will collaborate to…
